论文部分内容阅读
3例患者（例1女，52岁，有甲型肝炎史；例2女，64岁；例3女，61岁）均因慢性胃炎给予摩罗丹(浓缩丸)16丸口服、3次/d。例1无合并用药，例2合并使用雷贝拉唑钠肠溶片，例3合并使用雷贝拉唑钠肠溶片及瑞巴派特片。例1、例2、例3分别在服用摩罗丹(浓缩丸)27、22、19 d后出现肝功能异常，丙氨酸转氨酶（ALT）均升高>5倍参考值上限，例2、例3伴胆红素升高。例1、例2、例3均立即停用摩罗丹(浓缩丸)，分别在给予保肝治疗18、22、24 d后肝功能恢复正常。“,”Three patients (patient 1, a 52-year-old female, with a history of hepatitis; patient 2, a 64-year-old female; patient 3, a 61-year-old female) were all treated with n morodan concentrated pill (16 pills, thrice daily for all) for chronic gastritis. In patient 1, there were no combined drugs; in patient 2, sodium rabeprazole enteric-coated tablets were also used; in patient 3, sodium rabeprazole enteric-coated tablets and rebamipide tablets were combined. Patient 1, patient 2, and patient 3 developed abnormal liver function after 27, 22, and 19 days of n morodan concentrated pill administration, respectively. Their alanine aminotransferase (ALT) increased by more than 5 times the upper limit of the reference value, accompanied by elevated bilirubin in patient 2 and patient 3. All the 3 patients were stopped to use n morodan concentrated pill immediately. After 18, 22, and 24 days of liver-protective treatments, the liver function of patient 1, patient 2, and patient 3 returned to normal, respectively.n